NO20000542D0 - Endothelin antagonists - Google Patents
Endothelin antagonistsInfo
- Publication number
- NO20000542D0 NO20000542D0 NO20000542A NO20000542A NO20000542D0 NO 20000542 D0 NO20000542 D0 NO 20000542D0 NO 20000542 A NO20000542 A NO 20000542A NO 20000542 A NO20000542 A NO 20000542A NO 20000542 D0 NO20000542 D0 NO 20000542D0
- Authority
- NO
- Norway
- Prior art keywords
- endothelin antagonists
- endothelin
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/905,913 US6162927A (en) | 1994-08-19 | 1997-08-04 | Endothelin antagonists |
US4895598A | 1998-03-27 | 1998-03-27 | |
PCT/US1998/015479 WO1999006397A2 (en) | 1997-08-04 | 1998-07-27 | Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20000542D0 true NO20000542D0 (en) | 2000-02-02 |
NO20000542L NO20000542L (en) | 2000-04-04 |
Family
ID=26726720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20000542A NO20000542L (en) | 1997-08-04 | 2000-02-02 | Endothelin antagonists |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1003740A2 (en) |
JP (1) | JP2001512119A (en) |
CN (1) | CN1301264A (en) |
AU (1) | AU748469B2 (en) |
BG (1) | BG104216A (en) |
BR (1) | BR9815296A (en) |
CA (1) | CA2297894A1 (en) |
HU (1) | HUP0003484A3 (en) |
IL (1) | IL134175A0 (en) |
NO (1) | NO20000542L (en) |
NZ (1) | NZ502395A (en) |
PL (1) | PL342500A1 (en) |
SK (1) | SK1452000A3 (en) |
TR (4) | TR200101234T2 (en) |
TW (1) | TW552260B (en) |
WO (1) | WO1999006397A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU755530B2 (en) * | 1998-07-15 | 2002-12-12 | Bristol-Myers Squibb Company | Stereoselective reductive amination of ketones |
TWI306760B (en) | 2000-08-07 | 2009-03-01 | Abbott Lab | Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same |
US20040180925A1 (en) * | 2000-12-27 | 2004-09-16 | Kenji Matsuno | Dipeptidylpeptidase-IV inhibitor |
AR033465A1 (en) * | 2001-04-11 | 2003-12-17 | Abbott Lab | THE USE OF AN ENDOTHELINE RECEIVER ANTAGONIST IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT IN THE FAVORABLE MODULATION OF HEALTH-RELATED QUALITY AND TEMPORARY PROGRESSION ADJUSTED TO QUALITY RELATED TO HEALTH OF A PATIENT DISEASE |
FR2874015B1 (en) * | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | N- (1H-INDOLYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
FR2880625B1 (en) * | 2005-01-07 | 2007-03-09 | Sanofi Aventis Sa | N- (HETEROARYL) -1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE |
WO2007034406A1 (en) * | 2005-09-22 | 2007-03-29 | Actelion Pharmaceuticals Ltd | Pyrrolidine-3-carboxylic acid amide derivatives and their use as inhibitors of renin |
CA2697057A1 (en) | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
WO2011114103A1 (en) | 2010-03-18 | 2011-09-22 | Biolipox Ab | Pyrimidinones for use as medicaments |
JO2998B1 (en) | 2010-06-04 | 2016-09-05 | Amgen Inc | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer |
AU2012316055B2 (en) | 2011-09-27 | 2016-05-12 | Amgen Inc. | Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer |
WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
JP6266659B2 (en) | 2013-02-28 | 2018-01-24 | アムジエン・インコーポレーテツド | Benzoic acid derivative MDM2 inhibitors for the treatment of cancer |
CA2906538C (en) | 2013-03-14 | 2021-02-02 | Ana Gonzalez Buenrostro | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
JOP20200296A1 (en) | 2013-06-10 | 2017-06-16 | Amgen Inc | Processes of Making and Crystalline Forms of a MDM2 Inhibitor |
CN104262329A (en) * | 2014-10-22 | 2015-01-07 | 南京友杰医药科技有限公司 | Preparation method for anti-form atrasentan |
WO2023030470A1 (en) * | 2021-09-03 | 2023-03-09 | 深圳信立泰药业股份有限公司 | Endothelin a (eta) receptor antagonist compound, preparation method therefor and medical use thereof |
CN119487020A (en) * | 2022-07-25 | 2025-02-18 | 深圳信立泰药业股份有限公司 | Salt of endothelin A (ETA) receptor antagonist compound, preparation method and medical application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5013842A (en) * | 1990-01-22 | 1991-05-07 | Monsanto Company | Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors |
EP1186603A3 (en) * | 1994-08-19 | 2003-07-09 | Abbott Laboratories | Processes for preparing endothelin antagonists |
WO1997030046A1 (en) * | 1996-02-13 | 1997-08-21 | Abbott Laboratories | 4-(benzo-1,3-dioxolyl)-pyrrolidine-3-carboxylic acid derivatives as endothelin antagonists |
US5618949A (en) * | 1996-07-12 | 1997-04-08 | Abbott Laboratories | Process for synthesis of chiral cis- and trans-3-amino-4-substituted pyrrolidine compounds |
-
1998
- 1998-07-27 CA CA002297894A patent/CA2297894A1/en not_active Abandoned
- 1998-07-27 SK SK145-2000A patent/SK1452000A3/en unknown
- 1998-07-27 AU AU85921/98A patent/AU748469B2/en not_active Ceased
- 1998-07-27 CN CN98809462A patent/CN1301264A/en active Pending
- 1998-07-27 HU HU0003484A patent/HUP0003484A3/en unknown
- 1998-07-27 NZ NZ502395A patent/NZ502395A/en unknown
- 1998-07-27 TR TR2001/01234T patent/TR200101234T2/en unknown
- 1998-07-27 WO PCT/US1998/015479 patent/WO1999006397A2/en not_active Application Discontinuation
- 1998-07-27 EP EP98937139A patent/EP1003740A2/en not_active Ceased
- 1998-07-27 TR TR2001/01233T patent/TR200101233T2/en unknown
- 1998-07-27 BR BR9815296-3A patent/BR9815296A/en not_active Application Discontinuation
- 1998-07-27 IL IL13417598A patent/IL134175A0/en unknown
- 1998-07-27 JP JP2000505155A patent/JP2001512119A/en active Pending
- 1998-07-27 PL PL98342500A patent/PL342500A1/en not_active Application Discontinuation
- 1998-07-27 TR TR2005/01137T patent/TR200501137T2/en unknown
- 1998-07-27 TR TR2000/00993T patent/TR200000993T2/en unknown
- 1998-08-10 TW TW087112783A patent/TW552260B/en not_active IP Right Cessation
-
2000
- 2000-02-02 NO NO20000542A patent/NO20000542L/en not_active Application Discontinuation
- 2000-03-02 BG BG104216A patent/BG104216A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TR200101234T2 (en) | 2002-06-21 |
TR200501137T2 (en) | 2005-12-21 |
BR9815296A (en) | 2001-11-20 |
NZ502395A (en) | 2002-08-28 |
IL134175A0 (en) | 2001-04-30 |
NO20000542L (en) | 2000-04-04 |
PL342500A1 (en) | 2001-06-04 |
CA2297894A1 (en) | 1999-02-11 |
TR200101233T2 (en) | 2002-06-21 |
EP1003740A2 (en) | 2000-05-31 |
CN1301264A (en) | 2001-06-27 |
JP2001512119A (en) | 2001-08-21 |
HUP0003484A3 (en) | 2002-02-28 |
WO1999006397A3 (en) | 1999-12-09 |
BG104216A (en) | 2000-12-29 |
HUP0003484A2 (en) | 2002-01-28 |
TW552260B (en) | 2003-09-11 |
SK1452000A3 (en) | 2001-05-10 |
AU8592198A (en) | 1999-02-22 |
AU748469B2 (en) | 2002-06-06 |
WO1999006397A2 (en) | 1999-02-11 |
TR200000993T2 (en) | 2000-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE59811302D1 (en) | microemulsion | |
ID22500A (en) | SULFONAMIDA DOWN | |
DK0973746T3 (en) | Substituted 3-cyanoquinolines | |
ID24430A (en) | BENZAMIDINA DOWN | |
FI960953L (en) | Endothelin receptor antagonists | |
ID23173A (en) | TRISICLIC OR PIRAZOL PIROL DOWN | |
NO960473D0 (en) | Substituted biphenylsulfonamide endothelin antagonists | |
ATE228500T1 (en) | NPY ANTAGONISTS | |
NO20000542D0 (en) | Endothelin antagonists | |
BR9507220A (en) | Endothelin receptor antagonists | |
DE59813487D1 (en) | SUBSTITUTED 4-BENZOYL-PYRAZOLE | |
DE69636597D1 (en) | ENDOTHELIN RECEPTOR ANTAGONISTS | |
ZA985209B (en) | Endothelin antagonists | |
DE59710430D1 (en) | SUBSTITUTED 4-BENZOYL-PYRAZOLE | |
DE59807877D1 (en) | SUBSTITUTED 4-BENZOYL-PYRAZOLE | |
ID24079A (en) | AMINOHETEROXICLYLAMIDE SUBSTITUTED | |
DE69735842D1 (en) | tufting | |
FI972138A0 (en) | Returtraog i bestrykningsanordning | |
DE59810960D1 (en) | SUBSTITUTED PHENYLURACILE | |
KR980000586U (en) | Cutlery | |
ZA986908B (en) | Endothelin antagonists | |
DK0964867T3 (en) | tachykinin antagonists | |
ATE266645T1 (en) | SUBSTITUTED PHENYLURACILS | |
FR2771676B1 (en) | DELIVERED | |
BR9701096A (en) | Acertron iii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |